Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 5Phase 4 1Phase 1/2 1

Status

Completed 4Terminated 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Sarcoma 3Gynecologic 2

Conditions

Sarcoma 2Ovarian Neoplasms 2Peritoneal Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Fallopian Tube Neoplasms 1

Interventions

Cisplatin 186Carboplatin 181Paclitaxel 175Docetaxel 144Cyclophosphamide 129Dexamethasone 117pembrolizumab 106Doxorubicin 103Bevacizumab 103Gemcitabine 102Rituximab 96Prednisone 87Fluorouracil 86Pemetrexed 81Radiotherapy 77Vincristine 71Etoposide 71Capecitabine 69Nivolumab 68Trastuzumab 67Leucovorin 64Cytarabine 57Methotrexate 52Oxaliplatin 49atezolizumab 47Lenalidomide 43Ipilimumab 40Filgrastim 40Bortezomib 39Sorafenib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Has results × Trabectedin × Clear all
NCT04979442 2025-01-14

MANTRA

Rain Oncology Inc

Phase 3 Terminated
175 enrolled 16 charts
Sarcoma

Liposarcoma, Sarcoma

NCT01846611 2019-04-01

A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Janssen Research & Development, LLC

Phase 3 Completed
581 enrolled 14 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT01343277 2016-08-26

A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma

Janssen Research & Development, LLC

Phase 3 Completed
579 enrolled 13 charts
Sarcoma

Leiomyosarcoma

NCT00796120 2015-12-10

An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3 Completed
121 enrolled 10 charts
Sarcoma

Sarcoma

NCT00113607 2014-06-27

An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3 Completed
672 enrolled 14 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡